Note: You requested MDX-only Markdown for the blogpost, but the required output schema here expects a single string. Providing the MDX Markdown as a plain string.

India Glycols FY26: Margin expansion, strong bio-fuel cycle, and a demerger-led reset

India Glycols Limited closed FY26 with a cleaner balance sheet and stronger profitability, even as its businesses moved in different directions. Consolidated net revenue rose to INR 4,211 crore, up 11.8 percent year on year. EBITDA grew faster at INR 654 crore, up 24.5 percent, taking EBITDA margin to 15.5 percent from 13.9 percent a year ago. PAT increased to INR 293 crore, up 26.8 percent, with PAT margin expanding to 6.9 percent.

The Q4 snapshot was also solid. Net revenue increased 13.1 percent year on year to INR 976 crore, EBITDA rose 13.3 percent to INR 167 crore, and PAT jumped 35.7 percent to INR 87 crore. Management attributed the earnings lift to broad-based segment growth in the quarter and to lower finance costs following debt reduction.

A key FY26 feature was cash generation. The company reported cash flow from operations of INR 769 crore in FY26, up sharply year on year. That cash, along with a preferential allotment completed in November 2025, supported sizeable debt prepayment. Finance costs fell to INR 26 crore in Q4FY26 from INR 45 crore in Q4FY25.

Segment mix: Spirits and bio-fuel led growth, chemicals improved margins

FY26 consolidated segment performance showed a clear split between volume-driven growth segments and margin-improvement segments.

Potable Spirits delivered FY26 net revenue of INR 1,331 crore, up 14.4 percent year on year, with EBIT of INR 285 crore and an EBIT margin of 21.4 percent. Management highlighted continued market leadership in Uttar Pradesh and Uttarakhand, premiumisation actions, and expanding institutional channels such as CSD. In Q4FY26, Spirits revenue increased 7.9 percent to INR 306 crore, although EBIT declined to INR 68 crore.

Bio-fuel was the standout in FY26. Net revenue rose 40.9 percent to INR 1,470 crore and EBIT more than doubled to INR 115 crore, taking EBIT margin to 7.8 percent from 5.4 percent in FY25. Management linked the improved profitability to a stable grain cost environment, better DDGS realisations, and adequate feedstock availability supported by FCI rice allocation, alongside the policy tailwind of achieving 20 percent blending ahead of schedule.

Bio-based Specialties and Performance Chemicals (BSPC) saw revenue pressure but profit improvement. FY26 net revenue declined 10.4 percent to INR 1,203 crore, but EBIT increased 12.5 percent to INR 141 crore, and EBIT margin improved to 11.7 percent. On the call, management attributed topline weakness to competitive pressure in glycol ethers from lower-cost imports, volatility-driven decline in gases, and lower EO offtake by the JV during a period of pricing uncompetitiveness versus a large domestic petrochemical benchmark. At the same time, the company emphasized a shift away from low-margin business and highlighted strong traction in performance chemicals.

Ennature Biopharma remained the soft spot on profitability. FY26 net revenue was INR 208 crore (down versus INR 219 crore in FY25) and EBIT declined sharply to INR 7 crore, with EBIT margin at 3.5 percent. Management cited low nicotine sales and higher raw material prices for Gloriosa seeds in the API segment as key reasons for the margin pressure, while pointing to customer additions and momentum in branded nutraceutical initiatives.

Consolidated financial summary

Chemicals context: competitiveness cycles and portfolio reshaping

Management devoted meaningful time to the competitiveness cycle in ethylene oxide and ethanol-linked chemistry. The war-driven crude price rise and related availability concerns improved the relative position of ethanol-based routes, which management said helped margins and market competitiveness for EO and MEG in certain periods. However, they also acknowledged second-order impacts: export disruption in some oilfield chemical routes, higher prices and availability challenges for inputs like propylene oxide, and softening demand in select end-user markets.

The more important takeaway for investors was that the company is deliberately changing what it sells in chemicals. In FY26, the company accepted lower topline in some commoditised lines and highlighted growth in performance chemicals. Management stated that performance chemicals value and contribution were up more than 40 percent and expressed hope of more than doubling that business in the coming year, subject to project execution.

A structural earnings nuance also appeared in the call. Management noted that a meaningful portion of other income is linked to the joint venture and is economically integrated with the chemicals chain. In Q4, the company reported share of JV profit of INR 13 crore, compared with INR 11 crore in Q4FY25, while full-year JV profit share was INR 46 crore, flat year on year. The CFO also clarified that dividend received from the JV (INR 38.38 crore) is adjusted against investment as per accounting standards rather than being shown as income.

Spirits strategy: premiumisation, CSD traction, and measured geographic expansion

The Potable Spirits business continues to be a high-margin anchor for the consolidated P and L. FY26 EBIT margin stood at 21.4 percent, and management indicated there is no reason they cannot maintain such margins, with efforts aimed at improving mix.

On the call, the business team explained that the portfolio remains skewed toward IMIL by volume, but premium IMFL is gaining value share. Management discussed several actions: new product introductions in flavoured vodka and whisky categories, expansion in western UP with new stations, opening company-operated warehouses in UP, and expansion into new geographies such as Kerala. The investor deck also listed planned launches in Andhra Pradesh and Daman and Diu.

The institutional channel narrative was equally important. Management highlighted entry into CSD and described it as a lifetime registration process involving multiple screening stages. They also noted traction in paramilitary and defence supplies as an additional growth driver.

Bio-fuel: policy tailwinds, capacity context, and margin drivers

FY26 was a high-growth year for bio-fuel. Management noted that India has achieved the 20 percent blending target ahead of the original timeline. They also stated that the country now has excess ethanol capacity and that the government is considering increasing blending further.

The call included a detailed view on feedstock evolution. Management described a shift in India’s ethanol production mix toward grain, including increasing contribution from maize, and explained that stable grain prices and improving DDGS realisations supported margins. While the company did not provide explicit numeric guidance for FY27 bio-fuel profitability, it reiterated that ethanol blending is a long-term policy and that industry margins have historically remained reasonable through policy and market adjustments.

Capital allocation, leverage, and the proposed demerger

If FY26 was about margin expansion, the next phase appears to be about structure and capital discipline.

The CFO stated the company prepaid about INR 804 crore of debt in the quarter, funded by INR 467 crore equity raised in November 2025 and the rest through operating cash flow. Management also shared a scheduled repayment liability of about INR 268 crore in FY27 and indicated it would continue to prepay high-cost debt.

The largest corporate action is the proposed restructuring. The investor presentation lays out a demerger into three entities:

• India Glycols Limited for the chemicals business
• IGL Spirits Limited for the spirits and bio-fuel business
• Ennature Bio Pharma Limited for the bio pharma business and bio polymers (as per the proposed post-structure slide)

The company disclosed that the NCLT has admitted the application and a hearing was scheduled for 21 May 2026. On the call, management indicated it was hopeful of receiving the order in the first 10 days of June 2026 and then proceeding with ROC filing and other process steps.

The stated rationale is straightforward: clearer focus, more efficient capital allocation, reduced cross-business risk spillovers, and a potential value unlock by attracting focused investors to each business.

Takeaways

India Glycols ended FY26 with stronger profitability, better cash generation, and visible improvement in leverage metrics. Bio-fuel provided the most powerful growth tailwind, spirits remained a high-margin core business with ongoing premiumisation efforts, and chemicals improved profitability despite topline pressure through mix and portfolio pruning.

The two execution variables to watch are clear from management commentary. First is whether the chemicals growth pipeline, especially performance chemicals, can translate into sustained topline growth alongside margin strength. Second is whether Ennature Biopharma can recover margins through customer additions, better nicotine economics, and branded nutraceutical scaling.

Over the near term, the proposed demerger is likely to be the defining catalyst. If completed within the indicative timeline discussed, it will reset how investors evaluate the company, segment by segment, with cleaner accountability for capital allocation and returns.